Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 12 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell CancerWithdrawnNCT04834349Phase 2
• Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT04831450Phase 2
• Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2
• A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckCompletedNCT04830592Phase 1
• A Study to Assess Safety of Nivolumab in Routine Oncology Practice in ChinaCompletedNCT04825873
• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT04815720Phase 1/2
• A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL StudyStatus unknownNCT04814069Phase 2
• Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCCompletedNCT04811027Phase 2
• SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node IdentificationStatus unknownNCT04803331Not applicable
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)TerminatedNCT04801472Not applicable
• Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1TerminatedNCT04795713Phase 1
• Concurent Chemoradiotherapy in Head and Neck CancersStatus unknownNCT04780750Phase 3
• Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous TummorStatus unknownNCT04766827Phase 4
• RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and MelanomaTerminatedNCT04762225Phase 1
• Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in ChinaStatus unknownNCT04740996
• Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPCCompletedNCT04725396Not applicable
• Evaluation of OE-MRI in Patients With H&N CancerCompletedNCT04724096
• JAB-3068 Activity in Adult Patients With Advanced Solid TumorsCompletedNCT04721223Phase 1/2
• Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2
• Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)CompletedNCT04696744
• Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette UseCompletedNCT04694846Not applicable
• Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Active, not recruitingNCT04675333Phase 2
• Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)Active, not recruitingNCT04675294Phase 2
• Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.CompletedNCT04672772
• A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT04670679Phase 1
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and NeckStatus unknownNCT04664582Not applicable
• Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCCTerminatedNCT04659369Phase 1
• MIT-001 for Prevention of CCRT-Induced OM in HNSCC PatientsActive, not recruitingNCT04651634Phase 2
• SHR-1701 in Patients With Recurrent/Metastatic ScchnStatus unknownNCT04650633Phase 2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
• De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04638465
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)Active, not recruitingNCT04609280Phase 2
• A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Phase 1
• A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04603248Not applicable
• GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 TherapyCompletedNCT04601402Phase 1
• Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT04599309
• TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell TherapyTerminatedNCT04596033Phase 1
• NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing SurgeryTerminatedNCT04588038Phase 1
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal CancerCompletedNCT04572100Phase 1
• Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine LearningStatus unknownNCT04543266
• Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1
• Retreatment With Intratumoral Diffusing Alpha Radiation EmittersCompletedNCT04540588Not applicable
• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Active, not recruitingNCT04534205Phase 2/3
• Phonosurgical Augmentation After Laser Resection of Early Glottic CarcinomaCompletedNCT04525066Phase 2
• Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)Status unknownNCT04523883Phase 2
• Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/MelanomaCompletedNCT04490564
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck CancerCompletedNCT04474470Phase 1/2
• Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma PatientsCompletedNCT04473716Phase 1
• Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor MalignanciesTerminatedNCT04465487Phase 1
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
• Hemopurifier Plus Pembrolizumab in Head and Neck CancerTerminatedNCT04453046Not applicable
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid TumorsCompletedNCT04452214Phase 1
• Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck CancerActive, not recruitingNCT04452032Phase 2
• Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.TerminatedNCT04445064Phase 2
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• A Study of SBRT for Squamous Cell Carcinoma of the Head and NeckStatus unknownNCT04435938Phase 2
• Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell CarcinomaTerminatedNCT04428047Phase 2
• First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic TumorsCompletedNCT04417465Phase 1
• Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I TrialCompletedNCT04413214Phase 1
• HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck CancerActive, not recruitingNCT04403620Phase 1/2
• Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCCStatus unknownNCT04399785Phase 2
• Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and NeckCompletedNCT04397341Phase 2
• Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell CarcinomaCompletedNCT04393506Phase 1
• Myeloid-derived Suppressor Cells (MDSCs) in OSCC PatientsStatus unknownNCT04387682Not applicable
• A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell CarcinomaStatus unknownNCT04367909Phase 2
• Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04361409Phase 1
• Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsCompletedNCT04357873Phase 2
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1
• Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid TumorsTerminatedNCT04348916Phase 1
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1
• Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCCActive, not recruitingNCT04340258Phase 1/2
• An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsActive, not recruitingNCT04305795Phase 1/2
• MicroRNA Markers in Head and Neck CancersActive, not recruitingNCT04305366
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
• Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck TumorsActive, not recruitingNCT04297995Phase 2
• Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal CancerStatus unknownNCT04296747Phase 2
• Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsActive, not recruitingNCT04291105Phase 2
• CIML NK Cell in Head & Neck CancerCompletedNCT04290546Phase 1
• Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell CarcinomaCompletedNCT04284540Not applicable
• Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor FailureCompletedNCT04278092Phase 2
• Intratumoral Microdosing of Motolimod in HNSCCTerminatedNCT04272333Early Phase 1
• Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian PopulationStatus unknownNCT04270201
• Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1
• Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck RegionWithdrawnNCT04266470Not applicable
• A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA MethylationWithdrawnNCT04262388Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic CancersTerminatedNCT04260802Phase 1/2
• Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCCompletedNCT04260126Phase 2
• Epigenetic Changes in Head and Neck CancerCompletedNCT04260074
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma OutcomesCompletedNCT04253808Not applicable
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid MalignanciesTerminatedNCT04244552Phase 1
• Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT ImagingStatus unknownNCT04222543Phase 2
• Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Phase 1
• Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1

← Squamous Cell Carcinoma of Head and Neck overview